Citation Impact
Citing Papers
PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
2008
Metabolomic NMR Fingerprinting to Identify and Predict Survival of Patients with Metastatic Colorectal Cancer
2011
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Cryptochrome, Circadian Cycle, Cell Cycle Checkpoints, and Cancer
2005 StandoutNobel
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Hepatocellular carcinoma
2003 Standout
X4 and R5 HIV-1 Have Distinct Post-entry Requirements for Uracil DNA Glycosylase during Infection of Primary Cells
2010 StandoutNobel
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
2005
Role of S6K1 in regulation of SREBP1c expression in the liver
2011
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
IDH1andIDH2Mutations in Gliomas
2009 Standout
mTOR Signaling in Growth Control and Disease
2012 Standout
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
2008 Standout
R1 Resection by Necessity for Colorectal Liver Metastases
2008
Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs
2006
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Hepatobiliary surgery
2000
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
2007
Oxaliplatin (L-OHP): a new reality in colorectal cancer
1998
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Colorectal cancer
2013 Standout
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
2004 Standout
Colorectal cancer prevention and treatment
2000
Molecular mechanisms of cisplatin resistance
2011 Standout
Colorectal cancer
2019 Standout
Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
1998
Long-Term Results of Two-Stage Hepatectomy for Irresectable Colorectal Cancer Liver Metastases
2008
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Oesophageal carcinoma
2013 Standout
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
2007
Systemic amyloidosis
2015 Standout
Satraplatin: leading the new generation of oral platinum agents
2009
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
2007 Standout
HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION
1997
Strategies to Improve Long-Term Outcomes after Renal Transplantation
2002 Standout
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
1997
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Progression of Alphafetoprotein Before Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: A Critical Factor
2009
Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial
2002 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Reversibility of Acquired Amyloid Polyneuropathy After Liver Retransplantation
2013
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Clinical Management of Oxaliplatin-Associated Neurotoxicity
2005
Current Issues in Adjuvant Treatment of Stage II Colon Cancer
2006
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Pharmacological Modulation of Cisplatin Toxicity Rhythms with Buthionine Sulfoximine in Mice Bearing Pancreatic Adenocarcinoma (PO3)
1998
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
MetaboAnalyst 3.0—making metabolomics more meaningful
2015 Standout
The Clavien-Dindo Classification of Surgical Complications
2009 Standout
New Developments and Approaches in the Platinum Arena
2000
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Spermidine/Spermine N1-Acetyltransferase-1 Binds to Hypoxia-inducible Factor-1α (HIF-1α) and RACK1 and Promotes Ubiquitination and Degradation of HIF-1α
2007 StandoutNobel
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Complications of radiofrequency coagulation of liver tumours
2002
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
2007
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
2009 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
2001
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
2007
Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
2000
Cellular and molecular pharmacology of oxaliplatin.
2002
Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With Pharmacokinetics
1999
Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.
2003
NCCN Task Force Report: Management of Neuropathy in Cancer
2009
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
2007
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients
2004
A dual-targeting, p53-independent, apoptosis-inducing platinum(ii ) anticancer complex, [Pt(BDIQQ)]Cl
2014
Structural and Biochemical Studies of a Fluoroacetyl-CoA-Specific Thioesterase Reveal a Molecular Basis for Fluorine Selectivity
2010 StandoutNobel
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
The Role of Clock Genes in Pharmacology
2010
Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer
2003
Recent advances in the treatment of familial amyloid polyneuropathy
2012
Circadian Clock, Cancer, and Chemotherapy
2014 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
2003
mTORC1 Inhibition via Rapamycin Promotes Triacylglycerol Lipolysis and Release of Free Fatty Acids in 3T3‐L1 Adipocytes
2010
Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen
1999
Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
1999
Fluorodeoxyuridine Modulates Cellular Expression of the DNA Base Excision Repair Enzyme Uracil-DNA Glycosylase
2006
The role of spermidine/spermineN1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells
2007
Works of R. Adam being referenced
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
1999
Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas
2007
Symptomatic and provende novoamyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients
2011
Results after nonsurgical local treatment of primary liver malignancies
2000
Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.
1996
Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases
2003
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
2000
[Adult to adult living-related liver transplantation. The Paul-Brousse Hospital preliminary experience].
2001
Prevalence of dyslipidemia in liver transplant recipients.
1992